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Objective: We conducted a prospective study of 103 consecutive
patients with non–small cell lung cancer who underwent a curative
lobectomy to test whether circulating tumor cells detected in the
peripheral blood by means of reverse transcriptase-polymerase
chain reaction of carcinoembryonic antigen messenger RNA is a
prognostic indicator independent of tumor stage in patients with
non–small cell lung cancer.
Methods: We assayed for carcinoembryonic antigen messenger
RNA by means of reverse transcriptase-polymerase chain reaction
in peripheral blood taken at the time of diagnosis before an oper-
ation and again 2 to 3 weeks after an operation from patients with non–small cell
lung cancer who underwent a curative lobectomy between March 1996 and April
1998. We analyzed the prognostic value of carcinoembryonic antigen messenger
RNA expression in the patients with non-small cell lung cancer in a univariate and
multivariate manner.
Results: Patients with carcinoembryonic antigen messenger RNA in the preopera-
tive blood samples had a poor survival when compared with those without carci-
noembryonic antigen messenger RNA. Of these patients, the worst survival was
seen in those with carcinoembryonic antigen messenger RNA in the postoperative
blood samples. The multivariate stepwise analysis selected the preoperative carci-
noembryonic antigen messenger RNA expression (P  .0004; relative risk, 0.21)
and the pathologic stage of disease (P  .0002; relative risk, 1.43) as the indepen-
dent prognostic factors for survival.
Conclusions: The molecular detection of carcinoembryonic antigen messenger RNA
in the preoperative peripheral blood is an independent prognostic factor in patients
with non–small cell lung cancer who undergo a curative operation.
The detachment of tumor cells from the primary site and their con-sequent release into the circulation is one of the early events in themetastatic cascade. Although the presence of circulating tumor cellsdoes not necessarily correlate with the subsequent appearance ofsystemic disease, some such tumor cells might have the potential toestablish metastases and therefore might have a negative influence
on patient prognosis. Because the number of circulating cells might be very small,
methods for their detection need to be both sensitive and specific. Morphology, flow
cytometry, conventional cytogenetics, and immunocytochemistry have been used to
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detect circulating tumor cells.1 However, these techniques
are relatively insensitive and dependent on the interaction of
antibodies with tumor-associated cell-surface antigens.
These methods might yield false-positive results if the an-
tibodies cross-react with normal antigens or if the tumor
antigens are presented on host immune cells.1,2
Recent developments in molecular technology, including
the advent of the polymerase chain reaction (PCR), have
permitted the sensitive detection of circulating tumor cells
in the peripheral blood.1,3 Several researchers have used the
gene encoding carcinoembryonic antigen (CEA) as the tar-
get gene because CEA messenger RNA (mRNA) can be
detected in almost all epithelial cells, including cancer cells,
but not in nonepithelial cells.4,5 The reverse transcriptase-
polymerase chain reaction (RT-PCR) amplification method
for CEA mRNA is an efficient means of detecting circulat-
ing cancer cells in the peripheral blood.6 If CEA mRNA is
detected in blood samples, this implies the presence of
ectopic epithelial cells and hence, presumably, cancer cells.
However, CEA is not a specific marker of lung cancer
cells, and the technique does not allow for specific identi-
fication of tumor cells. Therefore, a positive finding of CEA
mRNA might merely indicate the presence of epithelial
cells. In addition, the relationship between circulating tumor
cells and the development of metastatic disease is not fully
understood, and there is ample evidence in the literature that
many patients with malignant disease have evidence of
circulating tumor cells, yet most of these patients do not
have systemic disease.7
Given this background, we conducted a prospective
study of 103 consecutive patients with non–small cell lung
cancer (NSCLC) who underwent a curative lobectomy to
test whether circulating tumor cells detected in the periph-
eral blood by means of RT-PCR of CEA mRNA are a
prognostic indicator in patients with NSCLC. The results of
the RT-PCR amplification for CEA mRNA in the preoper-
ative and postoperative blood samples from these patients
and its relationship to clinicopathologic factors have been
described in detail elsewhere.8 In brief, the occurrence of
positive CEA mRNA expression in the preoperative blood
samples was significantly higher in the pathologic T3 (pT3)
tumors (85%) compared with the pT1 and pT2 tumors (48%
and 57%, respectively; P  .0048), in the pathologic N1
(pN1) and pN2 tumors (67% and 100%, respectively) com-
pared with the pN0 tumors (44%, P  0.0001), and in
pathologic TNM (pTNM) stage IIA, IIB, and IIIA disease
(50%, 73%, and 100%, respectively) compared with stage
IA and IB disease (41% and 36%, respectively; P  .0001).
Similarly, the occurrence of positive CEA mRNA expres-
sion in the postoperative blood samples was significantly
higher in the pT3 tumors (50%) compared with the pT1 and
pT2 tumors (18% and 24%, respectively; P  .0090), in the
pN1 and pN2 tumors (17% and 59%, respectively) com-
TABLE 1. Patient characteristics
Characteristic (n  103)
Median age, y (range) 68 (35-83)
Sex, n (%)
Male 76 (74)
Female 27 (26)
Histology, n (%)
Adenocarcinoma 66 (64)
Squamous cell carcinoma 37 (36)
pT factor,*n (%)
T1 40 (39)
T2 37 (36)
T3 26 (25)
pN factor, n (%)
N0 70 (68)
N1 6 (6)
N2 27 (26)
pTNM stage, n (%)
IA 32 (31)
() () 18
() () 10
() () 1
() () 3
IB 25 (24)
() () 16
() () 6
() () 0
() () 3
IIA 4 (4)
() () 2
() () 1
() () 0
() () 1
IIB 15 (15)
() () 3
() () 7
() () 1
() () 4
IIIA 27 (26)
() () 0
() () 11
() () 0
() () 16
Sequence of vessel ligation,*n (%)
PV first 43 (42)
PA first 35 (34)
Mixed order 25 (24)
RT-PCR for CEA mRNA pattern, n (%)
() () 39 (38)
() () 35 (34)
() () 2 (2)
() () 27 (26)
pT, Pathologic T (tumor size); pN, pathologic N (regional lymph node
metastasis); pTNM, postoperative pathologic TNM staging determined
according to the classification of the International Union Against Cancer.9
*The sequence of pulmonary vessel ligation during surgical intervention:
PV first indicates that the pulmonary vein was ligated before the pulmonary
artery, PA first indicates that the pulmonary artery was ligated before
pulmonary vein ligation, and mixed order indicates random ligation of
pulmonary vein and pulmonary artery.
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pared with the pN0 tumors (17%, P .0007), and in pTNM
stage IIA, IIB, and IIIA disease (25%, 33%, and 59%,
respectively) compared with stage IA and IB disease (13%
and 12%, respectively; P  .0002). Now sufficient time has
elapsed to analyze the prognosis of patients with NSCLC in
a prospective study.
Patients and Methods
Patients
The 103 patients with NSCLC enrolled in this study underwent a
curative lobectomy with mediastinal lymph node dissection (R2) at
the Department of Surgery II, Kumamoto University Hospital, and
at the Department of Thoracic Surgery, Kumamoto Chuo Hospital,
between March 1996 and April 1998. Informed consent was ob-
tained from each patient, and the study was approved by the ethics
committees of our institutes. The clinicopathologic characteristics
of the 103 patients are summarized in Table 1.9 None of these
patients with NSCLC in this study received preoperative or post-
operative chemotherapy or radiotherapy.
Immunohistochemical staining for CEA revealed that positive
immunostaining was observed in the tumor cells of all the NSCLC
specimens, including squamous cell tumors and nonsquamous cell
tumors, although the staining intensity and the extent of cancer
cells varied.
RT-PCR for CEA mRNA
Blood samples were taken from an antecubital vein in 103 patients
with NSCLC at the time of diagnosis before the operation and
again 2 to 3 weeks after the operation. Total RNA extraction and
the RT-PCR for CEA mRNA were performed as described previ-
ously.10 An aliquot of the RT reaction mixture in all samples was
subjected to RT-PCR for -actin to monitor cDNA synthesis. This
RT-PCR assay could detect CEA mRNA at a cell frequency as low
as 10 malignant cells per 107 normal cells in an in vitro model.8
Figure 1. Overall survival in 103 patients with NSCLC who under-
went a curative lobectomy in terms of pTNM stage of disease.
Figure 2. Overall survival in 103 patients with NSCLC who under-
went a curative lobectomy in terms of preoperative and postop-
erative CEA mRNA status.
Figure 3. Overall survival in 103 patients with NSCLC who under-
went a curative lobectomy in terms of CEA mRNA expression
pattern.
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The technique is also highly specific because no control blood
samples from healthy volunteers were positive for CEA mRNA.8
In addition, another in vitro experiment showed that none of the
lysed cancer cells mixed with normal blood were positive for CEA
mRNA, suggesting that the detection of CEA mRNA by means of
the RT-PCR might represent viable, rather than dead, cancer cells
in the circulation.8
Survival Analysis
The major statistical end point of this study was survival, and this
was calculated from the day of operation to the day of death or the
last known date alive. Event time distribution was estimated with
the method of Kaplan and Meier.11 Differences between death
distributions were tested for statistical significance with the log-
rank test.12 For simultaneous control for the effects of many
variables on differences in death rates, a multivariate proportional
hazards regression model was used.13
Results
Univariate Analysis
The 103 patients in the present analysis constitute 100% of
our previous study population.8 There is no statistical dif-
ference in survival between patients with adenocarcinoma
and those with squamous cell carcinoma (P  .4240). Figure
1 shows overall survival curves generated on the basis of pT
factor, pN factor, and pTNM stage of disease. As expected,
each of these factors was found to have a significant effect on
survival when evaluated in a univariate analysis.
When the patient prognosis was analyzed in terms of the
results of the RT-PCR amplification for CEA mRNA in the
preoperative and postoperative blood samples, patients with
positive CEA mRNA blood samples had a significantly
shorter survival when compared with those with negative
CEA mRNA samples (Figure 2). Patients with CEA mRNA
in the preoperative blood samples had a poor survival; of
these patients, the worst survival was seen in those with
CEA mRNA in the postoperative blood samples (Figure 3).
In contrast, patients with persistently negative CEA mRNA
blood samples had better survivals than did patients with
any other expression patterns for CEA mRNA (Figure 3).
Next, the survival analysis regarding CEA mRNA expres-
sion patterns was repeated separately according to the
Figure 4. Overall survival in 103 patients with NSCLC who underwent a curative lobectomy in terms of CEA mRNA
expression pattern according to the pTNM stage.
Figure 5. Overall survival in 103 patients with NSCLC who under-
went a curative lobectomy in terms of the sequence of pulmonary
vessel ligation.
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pTNM stage. Patients with persistently positive CEA
mRNA blood samples are likely to have a poorer prognosis
when compared with patients with any other expression
patterns for CEA mRNA, although a statistically significant
difference in survival was obtained only in stage IB disease
(P  .0163, Figure 4).
We also examined whether the sequence of pulmonary
vein (PV) and pulmonary artery (PA) ligation in curative
lobectomy for NSCLC affects the prognosis of patients. As
shown in Figure 5, there was no statistical difference in
survival among 3 patterns of pulmonary vessel ligation
sequence. The median survival by patient characteristics is
shown in Table 2.
Multivariate Analysis
To verify the independent nature of the prognostic value of
CEA mRNA expression, we used multivariate analysis. Cox
regression analysis of overall survival, allowing for age,
sex, histologic type, pT factor, pN factor, pTNM stage,
sequence of pulmonary vessel ligation, preoperative CEA
mRNA status, and postoperative CEA mRNA status,
showed that preoperative CEA mRNA expression is the
single independent prognostic factor regarding survival
(P  .0001; relative risk, 0.17; Table 3). To eliminate the
effect of the inclusion of less important variables into the
model, we also performed stepwise regression analysis with
a 5% significance level. Through a stepwise method, the
model selected the pathologic stage of disease (P  .0002;
relative risk, 1.43) and the preoperative CEA mRNA ex-
pression (P  .0004; relative risk, 0.21; Table 4). Age, sex,
histologic type, pT factor, pN factor, sequence of vessel
ligation, and postoperative CEA mRNA expression were
not independent prognostic factors.
Discussion
An unresolved and most important question to clinicians is
whether circulating tumor cells detected in the peripheral
blood by means of RT-PCR of CEA mRNA have a prog-
nostic value. Despite the detection of a small amount of
tumor cells in the peripheral blood, lymph nodes, and bone
marrow by means of molecular analysis, such as PCR-based
methods, the exact relationship between these cells and the
development of recurrent disease in malignancies is not
fully understood. However, recent reports provided data
indicating that the presence of occult cancer cells in lymph
nodes or bone marrow increases the risk of relapse in
patients with colorectal14 and breast15 cancer. In the present
study we prospectively tested the prognostic value of the
presence of CEA mRNA in the peripheral blood of patients
with resectable NSCLC before and after an operation by
means of an RT-PCR assay. We have demonstrated that
patients with CEA mRNA in the preoperative blood sam-
ples had poor survival; of these patients, persistent evidence
of circulating tumor cells, as determined by using RT-PCR
for CEA mRNA, showed worse prognosis than those pa-
tients in whom evidence for circulating tumor cells no
longer exists. We also revealed that the preoperative CEA
mRNA expression is a prognostic indicator independent of
tumor stage.
The results of the current study should be interpreted
with appropriate caution, taking into account the small
sample size and the limited observation time. However, the
major clinical implication of our findings might be seen in
the potential opportunity for therapeutic setting and moni-
toring. Patients with CEA mRNA in the preoperative, post-
operative, or both blood samples might represent evidence
of residual disease, and thus even after curative operations
TABLE 2. Median survival times by patient characteristics
Characteristic
Median survival
(mo)
P value
(log rank)
Histology
Adenocarcinoma 40.0
Squamous cell carcinoma 24.0 .4240
pT factor
T1 34.0*
T2 30.0
T3 11.5 .0001
pN factor
N0 53.0*
N1 27.0
N2 12.0 .0001
pTNM stage
IA 53.0*
IB 51.0*
IIA 14.0*
IIB 14.0
IIIA 12.0 .0001
Sequence of vessel ligation†
PV first 35.0
PA first 28.0*
Mixed order 24.0 .7270
Preoperative CEA mRNA expression
() 26.0*
() 14.0 .0001
Postoperative CEA mRNA expression
() 51.0*
() 14.0 .0001
RT-PCR for CEA mRNA pattern
() () 24.0*
() () 14.0
() () 26.0*
() () 13.0 .0001
*The survival times were represented as the longest follow-up period of
the patients in a group because the median survival times were not able
to be calculated because of the small number of dead patients in a group.
†The sequence of pulmonary vessel ligation during surgical intervention:
PV first indicates that the pulmonary vein was ligated before the pulmonary
artery, PA first indicates that the pulmonary artery was ligated before
pulmonary vein ligation, and mixed order indicates random ligation of
pulmonary vein and pulmonary artery.
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for early stage NSCLC, consideration might be given for
adding combined multimodal therapy. The current study
might also indicate the possibility that evaluating a patient’s
peripheral blood status at appropriate intervals after the
operation and before recurrence could help to determine the
remaining potential for recurrence. Although several studies
have demonstrated the general benefit of adjuvant chemo-
therapy, individual risk evaluation is still warranted to de-
termine a patient’s optimal dosage, drug selection, and
duration of therapy. In addition, thus far there are no clin-
ically relevant means available to determine the efficacy of
adjuvant therapy in an individual patient until the disease
recurs. Monitoring the extent of minimal residual disease in
patients with NSCLC after primary treatment might help to
individually tailor a patient’s therapy, potentially improving
an individual’s chance for long-term remission.
Surgeons always worry that the surgical manipulation of
a tumor during an operation might enhance the shedding of
cancer cells into the bloodstream, resulting in an increase in
the occurrence of distant metastases. There is some evi-
dence indicating that intraoperative manipulation of a tumor
can enhance metastasis formation.16,17 We recently reported
that video-assisted thoracic surgery for NSCLC might in-
crease intraoperative hematogeneous dissemination of tu-
mor cells compared with an operation by means of conven-
tional open thoracotomy, as judged by detection of
circulating tumor cells expressing CEA mRNA by RT-
PCR.18 One surgical technique that might prevent such
shedding is to ligate the efferent vessels first. In lung car-
cinoma operations, ligating the PV before ligating the PA
has been postulated as a way to prevent tumor cell dissem-
ination into the bloodstream. Although there has been con-
siderable debate over this recommendation, it has not been
rigorously tested.
Using the RT-PCR amplification of CEA mRNA, we
previously examined whether vessel ligation sequence af-
fects the presence of circulating cancer cells and have
demonstrated that ligation of the PV before ligation of the
PA might partly prevent the release of tumor cells into the
bloodstream during a pulmonary lobectomy for NSCLC.10
These results seem to support the opinion that the PV should
be ligated first before the PA during surgical intervention
and that this order of vessel ligation might improve the
prognosis of patients with NSCLC. However, the present
study demonstrated that there was no difference in survival
among the 3 forms (PV first, PA first, and mixed) of
pulmonary vessel ligation. It is conceivable that most of the
cancer cells shed into the bloodstream during the operation
ultimately will be destroyed by natural defense mecha-
nisms, and very few of the tumor cells succeed in establish-
ing secondary tumors. However, it is also possible that some
tumor cells shed into the bloodstream by the surgical ma-
nipulation might survive in a selected subset of patients. The
long-term follow-up of our patient cohort will answer the
important question of whether the sequence of vessel liga-
tion will actually affect the prognosis of patients with
NSCLC who undergo a curative lobectomy and will also
provide data on the prognostic relevance of circulating
tumor cells in relation to a minimally invasive operation,
such as video-assisted lobectomy.
In conclusion, this is the first report showing that the
molecular detection of CEA mRNA in the peripheral blood
is an independent prognostic factor in patients with NSCLC.
Although large studies are still needed to explore the pos-
sibility of implementing a surrogate marker in the adjuvant
setting, we believe that there is increasing evidence that
detecting occult metastatic cells in the follow-up of patients
with cancer is feasible.19 This new approach might, in the
future, help clinicians to estimate an individual’s pending
TABLE 3. Cox proportional hazards regression analysis of variables
Variable z Score SE P value Relative risk
Age (60 y vs 60 y) 0.61 0.22 .201 1.68
Sex (male vs female) 0.86 0.30 .423 0.54
Histology (adenocarcinoma vs squamous cell carcinoma) 0.40 0.29 .157 1.50
pT factor (T1 vs T2 vs T3) 0.04 0.33 .898 1.04
pN factor (N0 vs N1 vs N2) 0.47 0.31 .133 0.62
pTNM stage (IA vs IB vs IIA vs IIB vs IIIA) 0.50 0.27 .062 1.65
Vessel ligation (PV first vs PA first vs mixed order)* 0.62 0.33 .062 0.54
Preoperative e CEA mRNA expression ( vs ) 1.79 0.45 .0001 0.17
Postoperative CEA mRNA expression ( vs ) 0.47 0.38 .211 0.62
*The sequence of pulmonary vessel ligation during surgical intervention: PV first indicates that the pulmonary vein was ligated before the pulmonary artery,
PA first indicates that the pulmonary artery was ligated before pulmonary vein ligation, and mixed order indicates random ligation of pulmonary vein and
pulmonary artery.
Table 4. Final stepwise regression analysis
Variable
z
Score SE
P
value
Relative
risk
pTNM stage 0.35 0.09 .0002 1.43
Preoperative CEA mRNA expression 1.58 0.44 .0004 0.21
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risk for recurrence and to individualize the duration of
treatment according to the presence or absence of occult
metastatic cells in the circulation of patients with NSCLC.
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